Briukhovetska, Daria http://orcid.org/0000-0002-2073-2335
Dörr, Janina http://orcid.org/0000-0001-9447-882X
Endres, Stefan http://orcid.org/0000-0002-4703-537X
Libby, Peter http://orcid.org/0000-0002-1502-502X
Dinarello, Charles A.
Kobold, Sebastian http://orcid.org/0000-0002-5612-4673
Article History
Accepted: 13 April 2021
First Online: 3 June 2021
Competing interests
: J.D. has received remuneration from Novartis for work unrelated to this Review. P.L. is an unpaid consultant to, or involved in clinical trials for, Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Novartis, Pfizer and Sanofi-Regeneron. P.L. is a member of scientific advisory board for Amgen, Caristo, Cartesian, Corvidia Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, PlaqueTec and XBiotech, Inc. P.L.’s laboratory has received research funding in the past 2 years from Novartis. P.L. is on the Board of Directors of XBiotech, and has a financial interest in Xbiotech, a company developing therapeutic human antibodies. P.L.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict-of-interest policies. S.K. and S.E. are inventors named on several patents in the field of immuno-oncology unrelated to the present work. S.K. and S.E. received research support from TCR2 Inc. and Arcus Bioscience for work unrelated to this Review. S.K. and S.E. have licensed intellectual property to TCR2 Inc. S.K. has received honoraria from GlaxoSmithKline and Novartis. D.B. and C.A.D. declare no competing interests.
Free to read: This content has been made available to all.